Project Grant R01CA301513
Award Date
5/21/25
Completion Date
5/31/30
Dollars Obligated
$525K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to Weill Medical College of Cornell University provides $710,980 over 5 years starting on Aug 1, 2024 to support research on the SPOP ubiquitin signaling pathway in prostate cancer. The project aims to: 1) Define the role of the upstream regulator G3BP1 in driving prostate tumorigenesis and the ability to target this axis, and 2) Establish the therapeutic potential of modulating the SPOP signaling...
The National Institute of General Medical Sciences (NIGMS) awarded a $667,480 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to St. Jude Children's Research Hospital Inc. The grant will fund a 5-year research project from May 1, 2025 to Apr 30, 2030 focused on advancing the understanding of chromatin dynamics and their role in gene expression, DNA replication, DNA repair, cell division, and differentiation. The research will combine structural biology, biochemistry,...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $148,568.00 to St. Jude Children's Research Hospital Inc. to investigate the mechanism by which a gene essential for rhabdoid tumor viability regulates chromatin function. The project aims to gain mechanistic insights into the interplay between the SWI/SNF chromatin remodeling complex and the polycomb complex, which is disrupted in rhabdoid tumors. The research will use molecular...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $683,979.00 to the Weill Medical College of Cornell University to conduct research on the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The research aims to: Define the propensity of prostate cancers harboring SPOP mutations to progress to specific subtypes of treatment-resistant castration-resistant prostate cancer (CRPC). Mechanistically...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to explore the role of aberrant splicing in cancer cell heterogeneity and its potential as a target for cancer immunotherapies. The $122,032 award, with a performance period from February 1, 2025 to January 31, 2027, is being provided to Weill Medical College of Cornell University, a prominent academic medical institution. The research aims to achieve three objectives: 1)...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $489,527 to Emory University to enhance the understanding of genetic variants in the SMARCB1 gene and their impact on the function of the SWI/SNF chromatin remodeling complex. The research project aims to assess over 99% of SMARCB1 mutations through deep mutagenesis scanning, determine the mechanisms behind key mutations that affect SMARCB1's ability...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides funding of $584,872 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research on the causes and consequences of genomic instability in myelodysplastic syndromes (MDS). The key objectives are to investigate the mechanisms by which mutations in RNA splicing factor genes trigger elevated cellular R-loops, and to evaluate the therapeutic potential of PARP...
This federal Project Grant award, valued at $462,500.00 and provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859), supports research to discover chemical modulators of RNA-protein assemblies through the systematic targeting of DEAD-box RNA-dependent ATPases. The key objectives of this multidisciplinary research program are to: Identify allosteric compounds that stabilize DEAD-box proteins in complex with...
This Project Grant award for $1,340,665.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to St. Jude Children's Research Hospital Inc. The award supports research focused on the FGFR pathway as a lead therapeutic vulnerability in pediatric ependymoma, a type of brain cancer in children. The project will be conducted over 3 years, from September 1, 2023 to August 31, 2026, and aims to advance the development of effective...
This federal Project Grant award of $502,516 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the impacts of newly developed small molecule nuclear heat shock transcription factor 1 (HSF1) degraders on acute myeloid leukemia (AML) stem cell self-renewal. The research aims to elucidate the mechanism of action of HSF1 degraders in leukemic stem cells and identify associated biomarkers to help predict patient...